Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SP

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Mar 23, 2023 9:51pm

189 Views

Post# 35357803

RE:RE:RE:RE:RE:SP

https://clinicaltrials.gov/ct2/results?cond=&term=Reolysin&cntry=&state=&city=&dist=

Gosh, notable, that took me about 5 seconds to find these trials.

Any concluded trial that does not progress to the next phase is by definition a failed trial.

Funny that new investors may never have heard of Reolysin. Brilliant move on ONC's part, even if it did require a little tiny lie about conflicting registered trademarks, etc. what was it? Reolysin rhymes with Bragopaleason so the FDA asked us to change our name. Yeah, sure.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing